
|Videos|December 13, 2020
Analysis of investigational ophthalmic solution for treating presbyopia-related symptoms
Author(s)Alex Delaney-Gesing , David Hutton
Michael R. Robinson, MD, Allergan, discusses the results from a study analyzing an investigational ophthalmic solution for treatment of symptoms associated with presbyopia presented during the virtual AAO 2020 meeting.
Advertisement
Michael R. Robinson, MD, vice president, Global Therapeutic Area Head, Ophthalmology at Allergan, an AbbVie company, discusses the results from a presentation titled, "Two Phase b Study Results for the Development of a Proprietary Formulation for the Treatment of Presbyopia," presented during the virtual AAO 2020 meeting.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
EURETINA 2026: OCT biomarkers that predict, preempt and pinpoint retinal disease
2
EURETINA 2026: nAMD imaging biomarkers and real-world switch outcomes
3
EURETINA 2026: Women’s health and pregnancy in the spotlight
4
EURETINA 2026: Why half-dose PDT leads the treatment of central serous chorioretinopathy
5










